Table of Contents
Table of Contents 3
List of Tables 7
List of Figures 9
Novartis AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 10
Novartis AG, Medical Equipment Deals By Type, 2012 to YTD 2018 11
Novartis AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 12
Novartis AG, Medical Equipment, Deals By Market, 2012 to YTD 2018 13
Novartis AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 14
Novartis AG, Medical Equipment, Deal Details 23
Asset Purchase 23
GSK Consumer Healthcare to Acquire Quell technology from NeuroMetrix 23
Advanced Accelerator Applications to Acquire Two Production Sites in Germany 24
Advanced Accelerator Applications Acquires Positron Emission Tomography from GE Healthcare 25
SensoMotoric Sells Ophthalmic Division To Alcon Labs 26
Venture Financing 27
Pear Therapeutics Raises USD50 Million in Series B Financing 27
ImaginAb Raises USD7.7 Million in Venture Financing 29
Rani Therapeutics Raises USD39 Million in Series D Financing 30
Lemonaid Health Raises USD11 Million in Series A Financing 32
Atlas Genetics Raises USD35 Million in Series D Financing 33
Seventh Sense Biosystems Raises USD10 Million in Series C Financing 35
Rox Medical Raises USD40 Million in Series E Financing 37
Cota Raises Funds through Venture Financing 38
Rani Therapeutics Raises Funds in Financing 39
Ra Pharma Raises USD58.5 Million in Series B Financing 41
Autonomic Technologies Raises Additional USD5.5 Million in Series D Financing 43
MyoPowers Medical Raises USD5 Million in Venture Financing 45
Rani Therapeutics Raises USD25 Million in Series C Venture Financing 46
Autonomic Technologies Raises USD38 Million in Series D Financing 47
Merganser Biotech Raises USD28 Million in Series A Financing 49
Encore Vision Raises USD1 Million in Venture Financing 50
Atlas Genetics Raises USD20 Million in Series C Financing 51
Transcend Medical Raises USD7.2 Million in Venture Financing 53
BioNano Genomics Raises USD53 Million in Series C Venture Financing 54
Encore Vision Raises USD1.7 Million in Venture Financing 56
Seventh Sense Biosystems Raises USD16 Million in Series B Financing 57
ImaginAb Raises USD21 Million in Series B Venture Financing 59
Transcend Medical Raises US$22 Million In Series C Venture Financing 60
Advanced Accelerator Applications Raises US$56 Million In Venture Financing 61
Wavetec Vision Systems Raises US$0.8 Million In Venture Financing 62
Encore Vision Secures USD5 Million in Venture Funding 63
Wavetec Vision Raises US$11 Million In Series D-2 Financing 64
Advanced Accelerator Raises US$6 Million In First Tranche Of Venture Financing 65
Proteus Digital Health Raises US$63 Million In Series F Financing Round 66
Health XL Raises Funds Through Venture Financing 67
Wavetec Vision Raises US$16.5 Million In Venture Financing 68
Advanced Animal Diagnostics Secures USD4 Million in Second Tranche of Series B Funding 69
ImaginAb Raises US$12.5 Million In Series A Financing 70
WaveTec Vision Raises US$1.5 Million In Venture Financing 71
Transcend Medical Secures USD16 Million in Series B Venture Funding 72
Private Equity 73
dievini Hopp BioTech Acquires Remaining Stake in LTS Lohmann Therapie-Systeme from Novartis and BWK 73
Partnerships 74
Novartis Enters into Collaboration and Licensing Agreement with Harvard University and Dana-Farber Cancer Institute 74
Alcon Enters into Licensing Agreement with Google for Smart Lens Technology 75
Klox Technologies Enters Into Licensing Agreement With Sandoz Canada 76
Adamis Pharma Enters into Distribution Agreement with Sandoz 77
Pear Therapeutics Enters into Agreement with Sandoz 78
Pear Therapeutics Enters into Agreement with Novartis 79
NuvoAir Enters into Agreement with Novartis 80
Advanced Accelerator Applications Enters into Distribution Agreement with Blue Earth Diagnostics 81
Propeller Health Enters into Agreement with Novartis Pharma 82
Itel Telecomunicazioni Enters into Agreement with Advanced Accelerator Applications 83
Alcon Laboratories Enters Into Partnership Agreement with PowerVision 84
Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 85
Alcon Laboratories Enters Into Partnership Agreement with TrueVision Systems 86
Novartis Enters into Agreement with Microsoft 87
MedinCell Enters into Agreement with Sandoz International 88
Thermo Fisher Scientific Enters into Agreement with Novartis and Pfizer 89
CorTechs Labs Enters into Agreement with Novartis Pharma 90
Eveon Enters into Agreement with Advanced Accelerator Applications 91
Qiagen Enters into Co-Development Agreement with Novartis 92
SomaLogic Extends Co-Development Agreement with Novartis 93
MolecularMD Enters Into Agreement With Novartis To Develop Companion Diagnostic Test For Chronic Myelogenous Leukemia 94
Advanced Accelerator Applications Enters Into Co-Development Agreement With University of Warsaw 95
Foundation Medicine Extends Co-Development Agreement With Novartis 96
Advanced Accelerator Enters into Licensing Agreement with Cancer Targeted Technology 97
Sunovion Pharma Enters into Licensing Agreement with Novartis 98
BioQuiddity Expands Licensing Agreement with Sandoz 99
Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 100
Novartis Enters into Licensing Agreement with Boston Scientific for Everolimus 101
Life Technologies Enters Into Licensing Agreement With Novartis 102
Themis Medicare Enters Into Licensing Agreement With Novartis India For Diclofenac Topical Gel 103
Equity Offering 104
Advanced Accelerator Applications Prices Public Offering of American Depositary Shares for USD172.5 Million 104
Advanced Accelerator Applications to Raise up to USD80 Million in IPO 106
Debt Offering 108
Novartis Raises USD925 Million in Public Offering of 0.5% Bonds Due 2023 108
Novartis Raises USD925 Million in Public Offering of 1.375% Notes Due 2030 109
Novartis Raises USD925 Million in Public Offering of 1.7% Notes Due 2038 110
Novartis Raises USD647.19 Million in Public Offering of International Bonds Due 2027 111
Novartis Raises USD1.3 Billion in Public Offering of International Bonds Due 2021 112
Novartis Raises USD561.78 Million in Public Offering of International Bonds Due 2028 113
Novartis Raises USD1.40 Billion in Public Offering of International Bonds Due 2023 114
Novartis Raises USD1.75 Billion in Public Offering of 3% Bonds Due 2025 115
Novartis Raises USD1.25 Billion in Public Offering of 4% Bonds Due 2045 116
Novartis Raises USD2.15 Billion in Public Offering of 3.4% Bonds Due 2024 117
Novartis Raises USD1.85 Billion in Public Offering of 4.4% Bonds Due 2044 118
Novartis Completes Public Offering Of 2.4% Senior Notes Due 2022 For US$1.5 Billion 119
Novartis Completes Public Offering Of 3.7% Senior Notes Due 2042 For US$500 Million 120
Asset Transactions 121
China NT Pharma to Acquire Miacalcic Injectable and Miacalcic Spray from Novartis for USD145 Million 121
Novartis Plans to Divest Assets of Alcon 122
Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 123
Acquisition 125
GlaxoSmithKline Acquires Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD13 Billion 125
Novartis Acquires Advanced Accelerator Applications for USD3.9 Billion 127
Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 129
Alcon Acquires Transcend Medical 131
Novartis May Acquire Genfit 132
Novartis Acquires Encore Vision 133
Novartis Acquires Ziarco Group 134
Advanced Accelerator Applications Acquires Remaining 49.9% Stake in Umbra Medical 135
Alcon Acquires WaveTec Vision Systems 136
Advanced Accelerator Applications Acquires Imaging Equipment 138
Advanced Accelerator Applications Acquires Barnatron 139
Advanced Accelerator Applications Acquires Catalana De Dispensacion 140
Novartis Acquires Vivacta For US$90 Million 141
Alcon Acquires Endure Medical Systems, Technology Surgical Microscopes Provider 142
Novartis AG – Key Competitors 143
Novartis AG – Key Employees 144
Novartis AG – Locations And Subsidiaries 146
Head Office 146
Other Locations & Subsidiaries 146
Recent Developments 164
Strategy And Business Planning 164
Sep 25, 2018: Novartis to cut more than 2000 jobs in Switzerland and UK 164
Sep 25, 2018: Novartis proposes to exit Grimsby UK site by end of 2020 as part of global manufacturing network transformation 165
Sep 11, 2018: Nova Medical Centers opens occupational medicine clinic in El Paso, Texas 166
Jul 02, 2018: Novartis plans to spin-off eye care unit into standalone entity 167
Financial Announcements 168
Jul 18, 2018: Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company 168
Apr 19, 2018: Novartis delivered a strong first quarter and acted to become a more focused medicines company 173
Oct 24, 2017: Novartis delivered growth on top and bottom line in all divisions in Q3 177
Jul 18, 2017: Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products 182
Apr 25, 2017: Novartis delivered sales growth across all divisions as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued 187
Jan 25, 2017: Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback 191
Corporate Communications 197
Aug 14, 2018: Novartis names Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer 197
May 16, 2018: Novartis announces changes to the Executive Committee 198
May 10, 2018: Novartis India reconstitutes Board appoints Milan Paleja as Vice Chairman Managing Director 199
Apr 19, 2018: Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer 200
Mar 12, 2018: Novartis announces changes to the Executive Committee to support strategic priorities 201
Dec 15, 2017: Novartis announces Oncology head to retire 202
Sep 04, 2017: Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018. 203
Aug 24, 2017: Novartis appoints Bertrand Bodson as Chief Digital Officer 204
May 08, 2017: Dr. Stephen S. Lane joins Alcon as Chief Medical Officer and Global Head Franchise Clinical Strategy 205
Feb 28, 2017: Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting 206
Government and Public Interest 207
Nov 28, 2017: Biosimilar drugs have the potential to save more than USD 54 billion 207
Product News 208
Jul 12, 2018: Novartis launches the Galaxies of Hope app, a digital experience for the Neuroendocrine Tumor (NET) cancer community 208
Jul 09, 2018: Microsoft and Partners Showcase a New ‘Molecule’ for Better Health Outcomes 209
Jul 06, 2018: Sandoz and its affiliate, Novartis Pharmaceuticals voluntarily recall select blister packages of products in the U.S. due to packaging requirements for child resistance 210
Apr 25, 2018: Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home 212
Jun 06, 2017: Alcon highlights product and service innovations at 40th BCLA, one of the largest international meetings dedicated to contact lenses 213
Other Significant Developments 215
Sep 11, 2018: Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis 215
May 16, 2018: At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth 216
Sep 29, 2017: Alcon flagship AcrySof intraocular lens reaches 100 million implants and counting 217
Jun 05, 2017: Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer 218
Mar 16, 2017: Alcon and Orbis celebrate new Flying Eye Hospital’s visit to the UK 219
Mar 03, 2017: Alcon Launches New Digital Vision Care Marketing Portal for Eye Care Professionals 220
Mar 02, 2017: Alcon Supports Eye Health with Charitable Giving of Nearly $73 Million in 2016 and Renews Commitment to Think About Your Eyes 221
Jan 26, 2017: Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report 222
Jan 26, 2017: Achievement of sales milestone for COPD products 223
Jan 25, 2017: Seebri / Ultibro Breezhaler 2016 sales reach $512 million triggering $5 million milestone receipt 224
Appendix 225
Methodology 225
About GlobalData 225
Contact Us 225
Disclaimer 225
Novartis AG, Medical Equipment, Key Facts, 2017 2
Novartis AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Novartis AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 10
Novartis AG, Medical Equipment Deals By Type, 2012 to YTD 2018 11
Novartis AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 12
Novartis AG, Deals By Market, 2012 to YTD 2018 13
Novartis AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 14
GSK Consumer Healthcare to Acquire Quell technology from NeuroMetrix 23
Advanced Accelerator Applications to Acquire Two Production Sites in Germany 24
Advanced Accelerator Applications Acquires Positron Emission Tomography from GE Healthcare 25
SensoMotoric Sells Ophthalmic Division To Alcon Labs 26
Pear Therapeutics Raises USD50 Million in Series B Financing 27
ImaginAb Raises USD7.7 Million in Venture Financing 29
Rani Therapeutics Raises USD39 Million in Series D Financing 30
Lemonaid Health Raises USD11 Million in Series A Financing 32
Atlas Genetics Raises USD35 Million in Series D Financing 33
Seventh Sense Biosystems Raises USD10 Million in Series C Financing 35
Rox Medical Raises USD40 Million in Series E Financing 37
Cota Raises Funds through Venture Financing 38
Rani Therapeutics Raises Funds in Financing 39
Ra Pharma Raises USD58.5 Million in Series B Financing 41
Autonomic Technologies Raises Additional USD5.5 Million in Series D Financing 43
MyoPowers Medical Raises USD5 Million in Venture Financing 45
Rani Therapeutics Raises USD25 Million in Series C Venture Financing 46
Autonomic Technologies Raises USD38 Million in Series D Financing 47
Merganser Biotech Raises USD28 Million in Series A Financing 49
Encore Vision Raises USD1 Million in Venture Financing 50
Atlas Genetics Raises USD20 Million in Series C Financing 51
Transcend Medical Raises USD7.2 Million in Venture Financing 53
BioNano Genomics Raises USD53 Million in Series C Venture Financing 54
Encore Vision Raises USD1.7 Million in Venture Financing 56
Seventh Sense Biosystems Raises USD16 Million in Series B Financing 57
ImaginAb Raises USD21 Million in Series B Venture Financing 59
Transcend Medical Raises US$22 Million In Series C Venture Financing 60
Advanced Accelerator Applications Raises US$56 Million In Venture Financing 61
Wavetec Vision Systems Raises US$0.8 Million In Venture Financing 62
Encore Vision Secures USD5 Million in Venture Funding 63
Wavetec Vision Raises US$11 Million In Series D-2 Financing 64
Advanced Accelerator Raises US$6 Million In First Tranche Of Venture Financing 65
Proteus Digital Health Raises US$63 Million In Series F Financing Round 66
Health XL Raises Funds Through Venture Financing 67
Wavetec Vision Raises US$16.5 Million In Venture Financing 68
Advanced Animal Diagnostics Secures USD4 Million in Second Tranche of Series B Funding 69
ImaginAb Raises US$12.5 Million In Series A Financing 70
WaveTec Vision Raises US$1.5 Million In Venture Financing 71
Transcend Medical Secures USD16 Million in Series B Venture Funding 72
dievini Hopp BioTech Acquires Remaining Stake in LTS Lohmann Therapie-Systeme from Novartis and BWK 73
Novartis Enters into Collaboration and Licensing Agreement with Harvard University and Dana-Farber Cancer Institute 74
Alcon Enters into Licensing Agreement with Google for Smart Lens Technology 75
Klox Technologies Enters Into Licensing Agreement With Sandoz Canada 76
Adamis Pharma Enters into Distribution Agreement with Sandoz 77
Pear Therapeutics Enters into Agreement with Sandoz 78
Pear Therapeutics Enters into Agreement with Novartis 79
NuvoAir Enters into Agreement with Novartis 80
Advanced Accelerator Applications Enters into Distribution Agreement with Blue Earth Diagnostics 81
Propeller Health Enters into Agreement with Novartis Pharma 82
Itel Telecomunicazioni Enters into Agreement with Advanced Accelerator Applications 83
Alcon Laboratories Enters Into Partnership Agreement with PowerVision 84
Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 85
Alcon Laboratories Enters Into Partnership Agreement with TrueVision Systems 86
Novartis Enters into Agreement with Microsoft 87
MedinCell Enters into Agreement with Sandoz International 88
Thermo Fisher Scientific Enters into Agreement with Novartis and Pfizer 89
CorTechs Labs Enters into Agreement with Novartis Pharma 90
Eveon Enters into Agreement with Advanced Accelerator Applications 91
Qiagen Enters into Co-Development Agreement with Novartis 92
SomaLogic Extends Co-Development Agreement with Novartis 93
MolecularMD Enters Into Agreement With Novartis To Develop Companion Diagnostic Test For Chronic Myelogenous Leukemia 94
Advanced Accelerator Applications Enters Into Co-Development Agreement With University of Warsaw 95
Foundation Medicine Extends Co-Development Agreement With Novartis 96
Advanced Accelerator Enters into Licensing Agreement with Cancer Targeted Technology 97
Sunovion Pharma Enters into Licensing Agreement with Novartis 98
BioQuiddity Expands Licensing Agreement with Sandoz 99
Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 100
Novartis Enters into Licensing Agreement with Boston Scientific for Everolimus 101
Life Technologies Enters Into Licensing Agreement With Novartis 102
Themis Medicare Enters Into Licensing Agreement With Novartis India For Diclofenac Topical Gel 103
Advanced Accelerator Applications Prices Public Offering of American Depositary Shares for USD172.5 Million 104
Advanced Accelerator Applications to Raise up to USD80 Million in IPO 106
Novartis Raises USD925 Million in Public Offering of 0.5% Bonds Due 2023 108
Novartis Raises USD925 Million in Public Offering of 1.375% Notes Due 2030 109
Novartis Raises USD925 Million in Public Offering of 1.7% Notes Due 2038 110
Novartis Raises USD647.19 Million in Public Offering of International Bonds Due 2027 111
Novartis Raises USD1.3 Billion in Public Offering of International Bonds Due 2021 112
Novartis Raises USD561.78 Million in Public Offering of International Bonds Due 2028 113
Novartis Raises USD1.40 Billion in Public Offering of International Bonds Due 2023 114
Novartis Raises USD1.75 Billion in Public Offering of 3% Bonds Due 2025 115
Novartis Raises USD1.25 Billion in Public Offering of 4% Bonds Due 2045 116
Novartis Raises USD2.15 Billion in Public Offering of 3.4% Bonds Due 2024 117
Novartis Raises USD1.85 Billion in Public Offering of 4.4% Bonds Due 2044 118
Novartis Completes Public Offering Of 2.4% Senior Notes Due 2022 For US$1.5 Billion 119
Novartis Completes Public Offering Of 3.7% Senior Notes Due 2042 For US$500 Million 120
China NT Pharma to Acquire Miacalcic Injectable and Miacalcic Spray from Novartis for USD145 Million 121
Novartis Plans to Divest Assets of Alcon 122
Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 123
GlaxoSmithKline Acquires Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD13 Billion 125
Novartis Acquires Advanced Accelerator Applications for USD3.9 Billion 127
Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 129
Alcon Acquires Transcend Medical 131
Novartis May Acquire Genfit 132
Novartis Acquires Encore Vision 133
Novartis Acquires Ziarco Group 134
Advanced Accelerator Applications Acquires Remaining 49.9% Stake in Umbra Medical 135
Alcon Acquires WaveTec Vision Systems 136
Advanced Accelerator Applications Acquires Imaging Equipment 138
Advanced Accelerator Applications Acquires Barnatron 139
Advanced Accelerator Applications Acquires Catalana De Dispensacion 140
Novartis Acquires Vivacta For US$90 Million 141
Alcon Acquires Endure Medical Systems, Technology Surgical Microscopes Provider 142
Novartis AG, Key Competitors 143
Novartis AG, Key Employees 144
Novartis AG, Subsidiaries 146
List of Figures
Novartis AG, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Novartis AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Novartis AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Novartis AG, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Novartis AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 10
Novartis AG, Medical Equipment, Deals by Type, 2012 to YTD 2018 11
Novartis AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 12
Novartis AG, Medical Equipment, Deals by Market, 2012 to YTD 2018 13
